S

Scholar Rock Holding Corp
D

SRRK

29.920
USD
3.25
(12.19%)
Market Closed
Volume
41,793
EPS
-3
Div Yield
-
P/E
-13
Market Cap
2,800,959,334
OverviewSignalsIdeasNews
Related Instruments
    C
    CHWY
    -0.710
    (-2.19%)
    31.690 USD
    F
    FATE
    -0.04500
    (-2.17%)
    2.02500 USD
    G
    GH
    -1.065
    (-3.53%)
    29.130 USD
    N
    NVTA
    0
    (0%)
    0.000000 USD
    P
    PSTG
    -1.620
    (-3.25%)
    48.210 USD
    R
    RDFN
    -0.32000
    (-3.68%)
    8.38000 USD
    R
    RGEN
    -17.400
    (-12.22%)
    124.960 USD
    T
    TDOC
    0.23500
    (2.62%)
    9.19500 USD
    T
    TWST
    -2.110
    (-5.42%)
    36.850 USD
    More
News

Title: Scholar Rock Holding Corp

Sector: Healthcare
Industry: Biotechnology
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.